Acute stroke management in patients with known or suspected atrial fibrillation.

[1]  B. Romner,et al.  Anticoagulation therapy a risk factor for the development of chronic subdural hematoma , 2013, Clinical Neurology and Neurosurgery.

[2]  D. Vivien,et al.  Endovascular treatment for acute ischemic stroke. , 2013, The New England journal of medicine.

[3]  Max Wintermark,et al.  A trial of imaging selection and endovascular treatment for ischemic stroke. , 2013, The New England journal of medicine.

[4]  Michael D Hill,et al.  Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.

[5]  M. Chimowitz.  Endovascular treatment for acute ischemic stroke--still unproven. , 2013, The New England journal of medicine.

[6]  Michela Ponzio,et al.  Endovascular treatment for acute ischemic stroke. , 2013, The New England journal of medicine.

[7]  A. Demchuk,et al.  The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial , 2013, Stroke.

[8]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[9]  Gustavo Saposnik,et al.  Atrial Fibrillation in Ischemic Stroke: Predicting Response to Thrombolysis and Clinical Outcomes , 2013, Stroke.

[10]  G. Hankey,et al.  Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation , 2012, The Lancet Neurology.

[11]  Gregory W Albers,et al.  Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial , 2012, The Lancet.

[12]  Elad I Levy,et al.  Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial , 2012, The Lancet.

[13]  A. Tripodi.  Laboratory tests and the new oral anticoagulants. , 2012, Thrombosis research.

[14]  S. Kiechl,et al.  Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis , 2012, Neurology.

[15]  K. Butcher,et al.  Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal , 2012, Stroke.

[16]  K. Lees,et al.  Impact of Atrial Fibrillation on Outcome in Thrombolyzed Patients With Stroke: Evidence From the Virtual International Stroke Trials Archive (VISTA) , 2012, Stroke.

[17]  Eric E. Smith,et al.  Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. , 2012, JAMA.

[18]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[19]  Gary A. Ford,et al.  Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score , 2012, Stroke.

[20]  S. Greenberg,et al.  The Pathophysiology and Clinical Presentation of Cerebral Amyloid Angiopathy , 2012, Current Atherosclerosis Reports.

[21]  J. Halperin,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[22]  A. Demchuk,et al.  Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study , 2012, The Lancet Neurology.

[23]  Martin O'Donnell,et al.  Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial , 2012, The Lancet Neurology.

[24]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[25]  Michael T. Mullen,et al.  Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[26]  Gordon H Guyatt,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[27]  A. Rabinstein,et al.  Symptomatic Intracranial Hemorrhage following Intravenous Thrombolysis for Acute Ischemic Stroke: A Critical Review of Case Definitions , 2012, Cerebrovascular Diseases.

[28]  A. Qureshi,et al.  Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment , 2012, Neurocritical Care.

[29]  J. C. Portilla-Cuenca,et al.  Fatal Intracerebral Hemorrhage Associated with Administration of Recombinant Tissue Plasminogen Activator in a Stroke Patient on Treatment with Dabigatran , 2011, Cerebrovascular Diseases.

[30]  S. Heiland,et al.  Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran , 2011, Stroke.

[31]  E. Wijdicks,et al.  Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis , 2011, Stroke.

[32]  F. Veith,et al.  Letter by Paraskevas et al regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/american Stroke Association". , 2011, Stroke.

[33]  Monica Acciarresi,et al.  Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta‐analysis of controlled studies , 2011, Journal of thrombosis and haemostasis : JTH.

[34]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the Europe , 2011, Journal of the American College of Cardiology.

[35]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[36]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[37]  S. Yusuf,et al.  Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.

[38]  RolfWachter,et al.  Enhanced Detection of Paroxysmal Atrial Fibrillation by Early and Prolonged Continuous Holter Monitoring in Patients With Cerebral Ischemia Presenting in Sinus Rhythm , 2010 .

[39]  T. Lindahl,et al.  Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays , 2010, Thrombosis and Haemostasis.

[40]  M. Flaherty.  Anticoagulant-associated intracerebral hemorrhage. , 2010, Seminars in neurology.

[41]  J. De Keyser,et al.  Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran , 2010, Cerebrovascular Diseases.

[42]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2010, Stroke.

[43]  Frank Beckers,et al.  Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. , 2010, American heart journal.

[44]  C. Sudlow,et al.  Antithrombotic Drug Use, Cerebral Microbleeds, and Intracerebral Hemorrhage: A Systematic Review of Published and Unpublished Studies , 2010, Stroke.

[45]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[46]  C. Anderson,et al.  Effects of Early Intensive Blood Pressure-Lowering Treatment on the Growth of Hematoma and Perihematomal Edema in Acute Intracerebral Hemorrhage: The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT) , 2010, Stroke.

[47]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[48]  J. Grotta,et al.  Anticoagulation after cardioembolic stroke: to bridge or not to bridge? , 2008, Archives of neurology.

[49]  P. Heuschmann,et al.  Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment , 2008, Cerebrovascular Diseases.

[50]  Gary A. Ford,et al.  Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.

[51]  Salim Yusuf,et al.  Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. , 2007, Journal of the American College of Cardiology.

[52]  Giancarlo Agnelli,et al.  Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials , 2007, Stroke.

[53]  M. O’Donnell,et al.  Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? , 2006, Stroke.

[54]  A David Mendelow,et al.  Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial , 2005, The Lancet.

[55]  R. Kronmal,et al.  Lessons from the Stroke Prevention in Atrial Fibrillation Trials , 2003, Annals of Internal Medicine.

[56]  P. Sandercock,et al.  Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial , 2001, Stroke.

[57]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[58]  E. Berge,et al.  Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study , 2000, The Lancet.

[59]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[60]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[61]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[62]  A. Ahuja,et al.  Low-molecular-weight heparin for the treatment of acute ischemic stroke , 1995 .

[63]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[64]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[65]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[66]  Douglas S. Lee,et al.  Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. , 2012, The Canadian journal of cardiology.

[67]  F. Rincon.  Intracranial Hemorrhage, Outcome, and Mortality After Intra-Arterial Therapy for Acute Ischemic Stroke in Patients Under Oral Anticoagulants , 2012 .

[68]  L. Mitchell,et al.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. , 2011, The Canadian journal of cardiology.

[69]  G. Moneta,et al.  Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke , 2009 .

[70]  P. Sandercock,et al.  Anticoagulants for acute ischaemic stroke. , 2008, The Cochrane database of systematic reviews.

[71]  P. Austin,et al.  Rate of stroke recurrence in patients with primary intracerebral hemorrhage. , 2000, Stroke.

[72]  E. Berge,et al.  Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. , 2000, Lancet.